Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opening Session Panel Discussion

Apr

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opening Session Panel Discussion

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Elisrasib Demonstrates High DCR in KRAS G12C NSCLC

Treatment Modifications and Outcomes for Older Adults With Advanced Cancer Who Prefer Preserving QOL vs Prolonging Survival

Zoldonrasib in Patients With KRAS G12D NSCLC Previously Treated With Chemoimmunotherapy

Advanced Platinum-Resistant Ovarian Cancer: Investigational ADC Shows Activity